Literature DB >> 11870384

Hepatitis C virus kinetics during and immediately after liver transplantation.

Montserrat Garcia-Retortillo1, Xavier Forns, Anna Feliu, Eduardo Moitinho, Josep Costa, Miquel Navasa, Antoni Rimola, Juan Rodes.   

Abstract

The study of hepatitis C virus (HCV) kinetics after liver transplantation (LT) might be important to design strategies to prevent HCV infection of the graft. We analyzed HCV kinetics during and immediately after LT in 20 consecutive patients undergoing LT for HCV-related cirrhosis. HCV RNA was quantified in blood samples obtained at regular intervals before, during, and after transplantation. HCV-RNA concentrations decreased in 18 of 20 patients during the anhepatic phase (mean decay slope -0.92, mean HCV elimination half-life 2.2 hours). We found a significant correlation between the HCV viral load decay and the blood loss during the anhepatic phase, indicating that the observed HCV clearance rates are maximum estimates. In fact, in 1 patient with an unusually long anhepatic phase of 20 hours and with minimum blood loss, the HCV elimination half-life was 10.3 hours. Eight to 24 hours after graft reperfusion a sharp decrease in HCV viral load occurred in 19 patients (mean decay slope -0.34, mean HCV elimination half-life 3.44 hours). HCV RNA became undetectable in only 1 patient. During the following days, HCV-RNA concentrations increased rapidly in 10 patients (mean HCV doubling time 13.8 hours), remained at similar levels in 4, and continued to decrease in 6. The only variable associated with a second-phase viral load decay was the absence of corticosteroids as part of the immunosuppressive regimen. In conclusion, a sharp decrease in HCV viral load occurs during the anhepatic phase and immediately after graft reperfusion, most likely owing to a lack of virion production and hepatic viral clearance. HCV infection of the graft, however, is an extremely dynamic process and viral replication begins a few hours after LT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870384     DOI: 10.1053/jhep.2002.31773

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  91 in total

1.  Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients.

Authors:  Ricardo Gehrau; Daniel Maluf; Kellie Archer; Richard Stravitz; Jihee Suh; Ngoc Le; Valeria Mas
Journal:  Mol Med       Date:  2011-04-20       Impact factor: 6.354

2.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

Review 3.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

4.  Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.

Authors:  Mark W Russo; Tarun Narang; Lon Eskind; Daniel Hayes; Vincent Casingal; Preston P Purdum; John S Hanson; Will Ahrens; James Norton; Herbert Bonkovsky
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

Review 5.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

6.  Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.

Authors:  Vijay Subramanian; Anil B Seetharam; Neeta Vachharajani; Venkataswarup Tiriveedhi; Nataraju Angaswamy; Sabarinathan Ramachandran; Jeffrey S Crippin; Surendra Shenoy; William C Chapman; Thalachallour Mohanakumar; Christopher D Anderson
Journal:  Transplantation       Date:  2011-12-15       Impact factor: 4.939

Review 7.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

8.  Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience.

Authors:  Sinziana Dumitra; Salleh I Alabbad; Jeffrey S Barkun; Teodora C Dumitra; Dimitrios Coutsinos; Peter P Metrakos; Mazen Hassanain; Steven Paraskevas; Prosanto Chaudhury; Jean I Tchervenkov
Journal:  HPB (Oxford)       Date:  2013-03-14       Impact factor: 3.647

9.  Hepatitis C Viral Kinetics in Special Populations.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2008

Review 10.  Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.

Authors:  Jan Peveling-Oberhag; Stefan Zeuzem; Wolf Peter Hofmann
Journal:  Med Microbiol Immunol       Date:  2009-11-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.